Creo Medical Group said the first patients had been successfully treated in the US using its 'Speedboat' medical device.
The device enabled the removal of cancerous and pre-cancerous gastrointestinal growths.
It used an electrosurgical generator that combined bipolar radiofrequency for precise, localised cutting and microwave for controlled coagulation.
Two surgeons from the same hospital were trained in the use of the device over the weekend and successfully used it on the patients this week.
Creo said it expected to increase the number of trained clinicians in the US as the roll-out of a company education programme continued.
At 1:51pm: (LON:CREO) Creo Medical Group Plc share price was +14p at 226p